Prolaio
We're Hiring!
Prolaio Company Growth, Stability & Outlook
What People Are Saying About Prolaio
-
Innovation-Driven Growth: Public materials cite 5–7 FDA-cleared algorithms, 20+ issued patents, and 4M+ hours of on-body data, plus a December 2025 FDA clearance for the eVO2peak module. The acquisition of physIQ further deepened digital biomarker capabilities and analytics.
-
Market Expansion: The company reports deployment across 22+ to 26+ countries and states plans to expand access into Europe and Asia by 2026. Integration into Kardigan’s platform is framed as extending reach to more patients and providers.
-
Strong Hiring & Retention: Hiring posture appears active with a dedicated careers page, multiple open roles on job hubs, and a listed 51–200 (≈80+) employee footprint. LinkedIn activity and recent hiring posts suggest ongoing team growth since early 2025.
